Nov. 14, 2007 “We always attend BIO-Europe in force.” Two leading pharma executives take a moment to talk about the priority they give to partnering for driving growth, and why BIO-Europe is the place they chose to implement that strategy.
Fresh from the hottest plenary discussion at BIO-Europe 2007, “A Day in the Life of Experienced Read more »
Nov. 14, 2007 Pick an easy number, like $10 million, and say that is the average amount a company might put into the first stages of an in-licensed biotech or pharma development program. Now multiply that number by 2,250, which is the number of people working on those programs who are attending BIO-Europe 2007 Read more »
Nov. 14, 2007 Top pharma dealmakers debate conflicting trends in biotech transactions. It was standing-room only for the plenary session devoted to “A Day in the Life of Experienced Dealmakers” on the second day of BIO-Europe 2007 in Hamburg.
Marking its fifth consecutive year, this provocative and highly popular session led by James Watson, Managing Director and Read more »
Nov. 14, 2007 Direvo Biotech AG Tuesday announced they have closed a collaboration agreement with Pfizer, Inc. to develop therapeutic proteases for different targets as potential treatments for various diseases. Direvo will apply its protein-engineering capabilities to create novel proteases with engineered specificity for these targets.
Direvo will use a protein engineering platform to discover Read more »
You could find Dr. Klaus Schoepe, the head of project management for Rentschler, at the entrance to the exhibition space for BIO-Europe’s exhibition area, when Schoepe was not in partner meetings.
“This is our sixth year at BIO-Europe, and of course we challenge the expense every year,” he said. “But then we look at the outcomes Read more »
The special signature of BIO-Europe is the powerful partnering system that manages the complex interactions between thousands of executives in the pharma-biotech industry from 46 countries.
This novel Web-based partnering system enables delegates to screen thousands of potential partners, pre-arrange and manage the meeting process.
While it is a structured tool driven by powerful algorithms for handling Read more »
Two years into an ambitious effort to build a biotech cluster for Malaysia, Azwan Ariffin, Vice President for Marketing at BioTechCorp from Kuala Lumpur said he always needs to start with the basics.
“A lot of people have trouble recalling where we are, let alone what we are doing in biotechnology,” he said.
Yet once potential partners Read more »
Quickly and efficiently reaching the U.S. pharmaceutical market is a critical goal for most biotechnology and pharmaceutical companies.
Whether going it alone or finding a strategic partner to help navigate the road to U.S. commercialization, today’s biotechnology companies have never faced a tougher or longer trip. Tightened financial markets, increased FDA regulatory oversight, Read more »
Newsletter